Switch theme
Sign up to access all valuation multiples
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
2014
n/a
LTM Revenue n/a
LTM EBITDA n/a
$22.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pilulka Lekarny has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pilulka Lekarny achieved revenue of $88.6M and an EBITDA of -$3.8M.
Pilulka Lekarny expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pilulka Lekarny valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $102M | $88.6M | n/a | n/a | XXX |
| Gross Profit | $9.9M | $10.8M | $7.0M | XXX | XXX |
| Gross Margin | 10% | 12% | NaN% | XXX | XXX |
| EBITDA | -$0.4M | -$3.8M | n/a | n/a | XXX |
| EBITDA Margin | 0% | -4% | NaN% | NaN% | XXX |
| Net Profit | -$1.1M | -$2.7M | -$7.3M | XXX | XXX |
| Net Margin | -1% | -3% | NaN% | XXX | XXX |
| Net Debt | n/a | n/a | $2.7M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Pilulka Lekarny's stock price is CZK 175 (or $7).
Pilulka Lekarny has current market cap of CZK 474M (or $19.7M), and EV of CZK 540M (or $22.4M).
See Pilulka Lekarny trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22.4M | $19.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Pilulka Lekarny has market cap of $19.7M and EV of $22.4M.
Pilulka Lekarny's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Pilulka Lekarny's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pilulka Lekarny and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $22.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPilulka Lekarny's NTM/LTM revenue growth is n/a
Pilulka Lekarny's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Pilulka Lekarny's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pilulka Lekarny's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pilulka Lekarny and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 15% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pilulka Lekarny acquired XXX companies to date.
Last acquisition by Pilulka Lekarny was XXXXXXXX, XXXXX XXXXX XXXXXX . Pilulka Lekarny acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pilulka Lekarny founded? | Pilulka Lekarny was founded in 2014. |
| Where is Pilulka Lekarny headquartered? | Pilulka Lekarny is headquartered in Czechia. |
| Is Pilulka Lekarny publicy listed? | Yes, Pilulka Lekarny is a public company listed on PRA. |
| What is the stock symbol of Pilulka Lekarny? | Pilulka Lekarny trades under PINK ticker. |
| When did Pilulka Lekarny go public? | Pilulka Lekarny went public in 2020. |
| Who are competitors of Pilulka Lekarny? | Similar companies to Pilulka Lekarny include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Pilulka Lekarny? | Pilulka Lekarny's current market cap is $19.7M |
| Is Pilulka Lekarny profitable? | Yes, Pilulka Lekarny is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
